UNCOVERED: Merck - Caught on Camera

Moderna Stock Skyrockets on Reports of U.S. Cancer Vaccine Initiative

Moderna stock gains on reports of an initiative to accelerate cancer vaccine development. Here’s why caution is warranted in playing MRNA shares at current levels.

Barchart · 10h ago

His Pancreatitis Had No Clear Cause Until Doctors Placing a Feeding Tube Spotted a Screw That Imaging Missed

A 78-year-old man's pancreatitis turned necrotizing with no clear cause. Then doctors found a metal screw in his gut that CT and X-rays missed.

Medical Daily · Oct 7

Vaxcyte's 31-Strain Pneumococcal Vaccine Met Its Main Antibody Goals Against Prevnar 20 and Capvaxive in Phase 3 Trial

Vaxcyte's VAX-31 met its main Phase 3 antibody goals vs. Prevnar 20 and Capvaxive in adults 50+, but the data are topline and approval is years away.

Medical Daily · Oct 7

Merck and Daiichi Withdraw Small Cell Lung Cancer Drug Bid After FDA Signals Phase 2 Data Fell Short

Merck and Daiichi pulled their bid for accelerated approval of I-DXd in small-cell lung cancer after FDA feedback. What patients should ask now.

Medical Daily · Sep 30

HHS Denies Kennedy Kept Gardasil Lawsuit Stake as Senators Question Fee Transfer to His Former Law Firm

HHS says Robert F. Kennedy Jr. kept no stake in Gardasil lawsuits. Four senators ask why his fee interest went to Wisner Baum instead of his son.

Medical Daily · Sep 28

A Blue Aorta Found During Valve Surgery Puts a Spotlight on EGPA, a Rare Vasculitis That Often Starts as Adult Asthma

Surgeons found a blue aortic lining in a woman with EGPA, a rare vasculitis that often begins as adult asthma. Why the heart is its main target.

Medical Daily · Sep 26

Kidney Cancer Patients Gain New Two-Pill Option as FDA Approves Belzutifan Combo Without Proven Survival Benefit

FDA approves belzutifan with lenvatinib for advanced kidney cancer after immunotherapy. It delayed tumor growth, but the survival gain was not significant.

Medical Daily · Sep 25

Opinion: The First Personalized mRNA Cancer Vaccine Just Passed a Major Test: Now Comes the Hard Part

A late-stage trial found that a custom-built mRNA therapy added to immunotherapy reduced melanoma recurrence. An oncologist argues the result is a genuine milestone, but patients deserve clear answers on the size of the benefit, survival, cost, and access before the hype takes over.

Medical Daily · Sep 23

This Dividend Stock Is Beating the Market in 2026 and Yields 2.36%

Merck is beating the market year-to-date after a jump on positive Phase 3 data, while paying an annualized dividend of about $3.40 for a yield above 2.3%.

Barchart · Sep 16

Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 Gains

Coca-Cola, Chevron, and Merck have outperformed the S&P 500 in 2026, each pairing strong share-price gains with growing dividends backed by solid fundamentals.

MarketBeat · Sep 14